Cargando…

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment

Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by the expansion of the CAG repeat in exon 1 of the huntingtin (HTT) gene, which results in a mutant protein with an extended polyglutamine tract. Inflammation occurs in both the brain and the periphery of HD patients and mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pido-Lopez, Jeffrey, Tanudjojo, Benedict, Farag, Sahar, Bondulich, Marie-Katrin, Andre, Ralph, Tabrizi, Sarah J., Bates, Gillian P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510744/ https://www.ncbi.nlm.nih.gov/pubmed/31076648 http://dx.doi.org/10.1038/s41598-019-43627-3

Ejemplares similares

In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease
por: Pido-Lopez, Jeffrey, et al.
Publicado: (2018)

Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
por: Bondulich, Marie Katrin, et al.
Publicado: (2021)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model
por: Mielcarek, Michal, et al.
Publicado: (2014)

Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease
por: Mielcarek, Michal, et al.
Publicado: (2014)

Serum tumor necrosis factor alpha increased during remission with Etanercept
por: Spirchez, Mihaela, et al.
Publicado: (2011)

Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models
por: Träger, Ulrike, et al.
Publicado: (2015)

Mislocalization of Nucleocytoplasmic Transport Proteins in Human Huntington’s Disease PSC-Derived Striatal Neurons
por: Lange, Jenny, et al.
Publicado: (2021)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

Human Huntington’s disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species
por: O’Regan, Grace C., et al.
Publicado: (2021)

Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington’S Disease Model
por: Landles, Christian, et al.
Publicado: (2020)

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington’s Disease
por: Osmand, Alexander P., et al.
Publicado: (2016)

Therapeutic Evaluation of Tumor Necrosis Factor-alpha Antagonist Etanercept against Traumatic Brain Injury in Rats: Ultrastructural, Pathological, and Biochemical Analyses
por: Hasturk, Askin Esen, et al.
Publicado: (2018)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Alternative processing of human HTT mRNA with implications for Huntington’s disease therapeutics
por: Fienko, Sandra, et al.
Publicado: (2022)

Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington’s Disease T Lymphocytes
por: Miller, James R. C., et al.
Publicado: (2015)

The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients
por: Waszczykowski, Michał, et al.
Publicado: (2020)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington’s disease mice
por: Bondulich, Marie K., et al.
Publicado: (2017)

The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients
por: Neueder, Andreas, et al.
Publicado: (2017)

FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat
por: Goold, Robert, et al.
Publicado: (2019)

Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.
por: Pusztai, L., et al.
Publicado: (1994)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha
por: Stanilov, Noyko, et al.
Publicado: (2014)

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
por: Ruder, Barbara, et al.
Publicado: (2019)

The Ubiquitin-Proteasome Reporter GFPu Does Not Accumulate in Neurons of the R6/2 Transgenic Mouse Model of Huntington's Disease
por: Bett, John S., et al.
Publicado: (2009)

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
por: Baraliakos, X, et al.
Publicado: (2005)

Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice
por: Shi, Xunlong, et al.
Publicado: (2013)

Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease
por: Moumné, Lara, et al.
Publicado: (2012)

Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).
por: Simonitsch, I., et al.
Publicado: (1998)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.
por: van der Zee, J., et al.
Publicado: (1995)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Tumour necrosis factor-alpha polymorphism as one of the complex inherited factors in pemphigus.
por: Torzecka, Jolanta Dorota, et al.
Publicado: (2003)

The promoting effect of tumour necrosis factor alpha in radiation-induced cell transformation.
por: Guo, R. F., et al.
Publicado: (1998)

Opioid receptor expression on neutrophils: effect of tumour necrosis factor alpha treatment
por: Schmidt, A, et al.
Publicado: (2007)

Tumour necrosis factor alpha-induced neuronal loss is mediated by microglial phagocytosis
por: Neniskyte, Urte, et al.
Publicado: (2014)

Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor
por: Chey, Shin Yee, et al.
Publicado: (2022)

Tumour Necrosis Factor Alpha (TNF-α) and Oral Squamous Cell Carcinoma
por: Brierly, Gary, et al.
Publicado: (2023)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mju5oipu2bgjjp1cihrjqlor84